Cervical cancer is the third leading cause of cancer death among females in less developed countries and the second most commonly diagnosed cancer. There were an estimated 5,27,600 new cervical cancer cases and 2,65,700 deaths worldwide in 2012. The current article describes the ESMO clinical guidelines for diagnosis, treatment, and follow-up of cervical cancer. Human Papillomavirus( HPV) is the most significant cause of cervical cancer. Prophylactic administration of HPV vaccine can effectively prevent infection and disease associated with the vaccine HPV types.
For many years, the Papanicolaou (Pap) test has been the standard method for cervical cancer screening, reducing the incidence by 60%–90% and the death rate by 90%. However, it has some limitations. More recently, an HPV DNA test has been introduced as a screening tool and, many studies have proved its sensitivity. The World…
